

Chris Zirzow, Vice President of Pharmaceutical Alliances at A-S Medication Solutions, LLC, is the clinical pharmacist who acts as a liaison between our physicians, regulatory, production, sales and customer service departments, so she is always up-to-date on the happenings in the medical industry.

## DRUGS GOING OFF PATENT

Starting in 2010, the pharmaceutical industry faces one of the biggest waves of patent expirations ever, affecting dozens of top-selling drugs. Here are some of the drugs facing looming generic competition, and their most recent sales numbers.

Brand name	Company	Generic name	Uses	Estimated patent expiration	Received FDA approval	Global sales, 3Q 2007 (in millions of dollars)
Crestor	AstraZeneca	Rosuvastatin	Cholesterol	2012	2003	\$691
Seroquel	AstraZeneca	Quetiapine	Antipsychotic	2011	1997	\$1,055
Symbicort	AstraZeneca	Budesonide+formoterol	Asthma	2012	2000	\$371
Plavix	Sanofi-Aventis / Bristol-Myers Squibb	Clopidogrel	Anticoagulant	2011	1998	\$1,250
Aricept	Pfizer / Eisai	Donepezil HCl	Alzheimer's	2010	1996	\$100
Lexapro	Forest Laboratories / H. Lundbeck	Escitalopram	Antidepressant	2012	2002	\$559
Avandia	GlaxoSmithKline	Rosiglitazone	Type 2 diabetes	2012	1999	\$463
Advair/Seretide	GlaxoSmithKline	Fluticasone, propionate+salmeterol	Asthma	2010	1998/1999	\$1,721
Levaquin	Johnson & Johnson	Levofloxacin	Antibiotic	2010	1996	\$366
Zyprexa	Eli Lilly	Olanzapine	Antipsychotic	2011	1996	\$1,166
Actos	Eli Lilly / Takeda	Pioglitazone	Type 2 diabetes	2011	1999	\$180
Singulair	Merck	Montelukast	Asthma	2012	1998	\$1,018
Diovan/Co-Diovan	Novartis	Valsartan+hydrochlorothiazide	Hypertension (high blood pressure)	2012	1996	\$1,267
Zometa	Novartis	Zoledronic acid	Cancer	2012	2001	\$318
Lipitor	Pfizer	Atorvastatin	Cholesterol	2011*	1996	\$3,170
Xalatan	Pfizer	Latanaprost	Glaucoma	2011	1995	\$402
Taxotere	Sanofi-Aventis	Docetaxel	Cancer	2010	1995	\$694
Aprovel	Sanofi-Aventis / Bristol-Myers Squibb	Irbesartan	Hypertension (high blood pressure)	2011	1998	\$392

\*Lipitor may face patent expiration in 2010, not 2011.

Sources: Datamonitor; Dolphin; WSJ.com research